Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60

Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.55

Targeting metabolic transformation for cancer therapy. Nat Rev Cancer (2010) 5.90

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol (2010) 5.08

Targeting the mTOR signaling network for cancer therapy. J Clin Oncol (2009) 4.52

Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov (2011) 4.05

Targeting the cancer kinome through polypharmacology. Nat Rev Cancer (2010) 3.74

Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol (2010) 3.20

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol (2009) 3.18

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest (2010) 3.11

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest (2011) 3.00

Regulation of TFEB and V-ATPases by mTORC1. EMBO J (2011) 2.84

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84

mTOR signaling and drug development in cancer. Nat Rev Clin Oncol (2010) 2.77

A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol (2012) 2.77

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer (2013) 2.61

PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res (2009) 2.32

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol (2015) 2.30

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol (2010) 2.27

Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol (2010) 2.26

Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer (2011) 2.13

The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox. Cell Cycle (2010) 2.10

Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med (2009) 2.09

The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res (2010) 2.03

Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov (2011) 2.01

Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the Start. Mayo Clin Proc (2015) 1.99

Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment. Int J Biochem Cell Biol (2011) 1.97

Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol (2012) 1.95

Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol (2014) 1.95

Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist (2011) 1.92

The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol (2012) 1.90

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther (2013) 1.90

Energy balance, host-related factors, and cancer progression. J Clin Oncol (2010) 1.85

A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med (2012) 1.84

Molecular diagnosis and therapy of kidney cancer. Annu Rev Med (2010) 1.82

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol (2010) 1.81

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia (2010) 1.81

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol (2011) 1.73

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol (2009) 1.70

Targeting mTOR dependency in pancreatic cancer. Gut (2014) 1.65

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer (2013) 1.65

Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int (2013) 1.63

Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities. Eur Respir J (2014) 1.59

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov (2010) 1.59

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59

State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58

FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell (2010) 1.58

Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability. PLoS One (2014) 1.57

Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res (2014) 1.57

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer (2012) 1.54

Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res (2009) 1.53

Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. Clin Cancer Res (2015) 1.53

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br J Cancer (2011) 1.53

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer (2010) 1.52

Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol (2012) 1.50

Can Urol Assoc J (2009) 1.49

Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res (2012) 1.49

Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS One (2011) 1.48

A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer (2015) 1.47

Renal cell carcinoma. BMJ (2014) 1.45

Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer (2010) 1.42

PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells. Cancer Cell Int (2015) 1.42

Everolimus. Clin Cancer Res (2010) 1.42

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer (2011) 1.41

Combining allogeneic immunotherapy with an mTOR inhibitor for advanced renal cell carcinoma. Bone Marrow Transplant (2009) 1.40

mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett (2013) 1.40

Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer (2013) 1.39

mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res (2009) 1.39

Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther (2011) 1.38

Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol (2010) 1.37

Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition. PLoS One (2012) 1.37

Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res (2010) 1.37

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer (2012) 1.35

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals. Transl Oncol (2010) 1.35

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther (2010) 1.34

Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol (2011) 1.33

Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol (2010) 1.33

Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs (2010) 1.33

Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol Cancer Res (2011) 1.33

Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol (2012) 1.33

Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One (2011) 1.32

Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PLoS One (2013) 1.32

New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am (2011) 1.31

Everolimus. Nat Rev Drug Discov (2009) 1.29

Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. Arterioscler Thromb Vasc Biol (2009) 1.29

Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2009) 1.27

EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem (2010) 1.27

Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer (2011) 1.27

Updates of mTOR inhibitors. Anticancer Agents Med Chem (2010) 1.27

Treating breast cancer in the 21st century: emerging biological therapies. J Cancer (2013) 1.26

Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer (2011) 1.26

Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol (2011) 1.24

From drug discovery to biomarker-driven clinical trials in lymphoma. Nat Rev Clin Oncol (2012) 1.24

Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer (2009) 1.24

Treatment of metastatic renal cell carcinoma. Nat Rev Urol (2010) 1.24

Renal cancer in von Hippel-Lindau disease and related syndromes. Nat Rev Nephrol (2013) 1.23

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene (2013) 1.23

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr Drugs (2012) 1.22

Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol (2010) 1.22

Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol (2009) 1.21

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39

Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94

Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13

Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.55

Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 7.80

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93

Renal cell carcinoma. Lancet (2009) 6.92

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86

Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol (2014) 6.64

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res (2009) 5.99

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (2013) 5.82

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet (2012) 5.67

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol (2008) 5.28

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol (2009) 5.05

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.91

Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet (2011) 4.79

Treatment of metastatic melanoma: an overview. Oncology (Williston Park) (2009) 4.58

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol (2012) 4.58

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2011) 4.52

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol (2010) 4.43

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet (2008) 4.11

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood (2004) 3.84

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol (2013) 3.79

Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol (2012) 3.65

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 3.65

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53

Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol (2013) 3.48

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am (2003) 3.44

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol (2013) 3.31

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol (2007) 3.26

Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res (2003) 3.25

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol (2013) 3.20

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol (2009) 3.18

Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol (2005) 3.15

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol (2003) 3.10

Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol (2004) 3.06

Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol (2008) 3.06

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol (2002) 3.05

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol (2008) 3.00

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93

Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol (2002) 2.91

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 2.88

Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer (2004) 2.80

Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol (2011) 2.68

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer (2013) 2.61

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol (2012) 2.56

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51

Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. J Urol (2009) 2.43

NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer (2007) 2.38

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol (2004) 2.37

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer (2007) 2.34

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol (2013) 2.29